Quoin Pharmaceuticals, Ltd. — Proxy Solicitation & Information Statement 2017

Nov 7, 2017

6-K 1 f6k110617_cellectbiotech.htm REPORT OF FOREIGN PRIVATE ISSUER

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Field: Rule-Page

Field: /Rule-Page

Form 6-K

Field: Rule-Page

Field: /Rule-Page

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2017

Commission File Number 001-37846

Field: Rule-Page

Field: /Rule-Page

CELLECT BIOTECHNOLOGY LTD.

(Translation of registrant’s name into English)

Field: Rule-Page

Field: /Rule-Page

23 Hata’as Street

Kfar Saba, Israel 44425

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

On November 7, 2017, Cellect Biotechnology Ltd. (the “Company”) announced that it will hold an Extraordinary General Meeting of Shareholders on December 13, 2017 at 11.00 a.m. (Israel time) at the offices of the Company’s legal counsel, Doron, Tikotzky, Kantor, Gutman, & Gross., at B.S.R. 4 Tower, 33 Floor, 7 Metsada Street, Bnei Brak, Israel. In connection with the meeting, the Company furnishes the following documents:

1. A copy of the Notice and Proxy Statement with respect to the Company’s Extraordinary General Meeting of Shareholders describing the proposals to be voted upon at the meeting, the procedure for voting in person or by proxy at the meeting and various other details related to the meeting, attached hereto as Exhibit 99.1;

2. A form of Proxy Card whereby holders of ordinary shares of the Company may vote at the meeting without attending in person, attached hereto as Exhibit 99.2; and

3. A form of Voting Instruction Card whereby holders of American Depositary Shares of the Company may vote at the meeting without attending in person, attached hereto as Exhibit 99.3.

Exhibit
99.1	Notice and Proxy Statement with respect to the Company’s
Extraordinary General Meeting of Shareholders
99.2	Proxy Card for holders of ordinary shares with respect to the
Company’s Extraordinary General Meeting of Shareholders
99.3	Voting Instruction Card for American Depositary Share holders
with respect to the Company’s Extraordinary General Meeting of Shareholders

Field: Page; Sequence: 2

2

Field: /Page

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| /s/
Eyal Leibovitz |
| --- |
| Name:
Eyal Leibovitz |
| Title:
Chief Financial Officer |

3